ArticleEuropean journal of pediatrics2026
Evaluation of thyroid function and thyroid volume in pediatric epileptic patients receiving levetiracetam monotherapy.
Article in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epilepsy is a common neurological disorder in childhood, and levetiracetam, a newer anti-seizure medication (ASM), is widely used due to its efficacy and safety. Recent attention has focused on the effects of anti-seizure medication (ASM) on thyroid function. This study aimed to evaluate changes in thyroid function and thyroid volume in children receiving levetiracetam monotherapy. It is the first study to assess both thyroid function tests and ultrasonographic thyroid volume in this context. In this single-center, prospective study, 40 children aged 3 months to 18 years with epilepsy who began levetiracetam monotherapy at Dr. Behçet Uz Children's Hospital between January and June 2024 were included. Thyroid function tests (fT3, fT4, TSH, Anti-TPO, Anti-Tg) and thyroid volume (via ultrasound) were measured before treatment and at the 6th month, and analyzed using age-adjusted standard deviation scores (SDS). No statistically significant differences were found between baseline and 6th-month values for fT3 (p = 0.678), fT4 (p = 0.604), TSH (p = 0.210), Anti-TPO (p = 0.923), or Anti-Tg (p = 0.843). Thyroid volume showed no significant change (p = 0.159), but thyroid volume SDS decreased significantly (p = 0.018).
conclusionLevetiracetam monotherapy over six months did not significantly affect thyroid hormone levels, autoantibodies, or absolute thyroid volume, although a decrease in thyroid volume SDS was noted. This may be due to measurement variability. Overall, short-term levetiracetam use appears safe in terms of thyroid function. WHAT IS KNOWN: • Levetiracetam is widely used in pediatric epilepsy and is considered to have a favorable safety profile with respect to endocrine function. • Previous studies suggest that levetiracetam has minimal effects on thyroid function in children, although the available data are limited. WHAT IS NEW: • This prospective study evaluates both thyroid function tests and ultrasonographic thyroid volume in children receiving levetiracetam monotherapy. • Over a six-month follow-up period, thyroid hormone levels and autoantibody profiles remained stable, with no clinically relevant change in absolute thyroid volume, although a mild decrease in thyroid volume standard deviation score was observed.
Indexed as
Identifiers
41582223What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.